Strategic Decisions and Risk Assessment in Production Cell Line Development
Many different approaches are available to develop high expressing mammalian cell lines for production of therapeutic proteins or antibodies. Decisions on which approach to use will be made based on whether productivity, speed to clinic, suitability for a platform process, or other criteria are the most important. This presentation includes a strategic analysis of different expression technologies, host cell lines, and screening and selection methods for development of high expressing production cell lines. An assessment of risks and benefits of different approaches are also discussed.